First Time Loading...

Molecular Templates Inc
NASDAQ:MTEM

Watchlist Manager
Molecular Templates Inc Logo
Molecular Templates Inc
NASDAQ:MTEM
Watchlist
Price: 1.47 USD -1.01% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

MTEM's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. [ Read More ]

The intrinsic value of one MTEM stock under the Base Case scenario is 3.52 USD. Compared to the current market price of 1.47 USD, Molecular Templates Inc is Undervalued by 58%.

Key Points:
MTEM Intrinsic Value
Base Case
3.52 USD
Undervaluation 58%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Molecular Templates Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MTEM stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Molecular Templates Inc

Provide an overview of the primary business activities
of Molecular Templates Inc.

What unique competitive advantages
does Molecular Templates Inc hold over its rivals?

What risks and challenges
does Molecular Templates Inc face in the near future?

Has there been any significant insider trading activity
in Molecular Templates Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Molecular Templates Inc.

Provide P/S
for Molecular Templates Inc.

Provide P/E
for Molecular Templates Inc.

Provide P/OCF
for Molecular Templates Inc.

Provide P/FCFE
for Molecular Templates Inc.

Provide P/B
for Molecular Templates Inc.

Provide EV/S
for Molecular Templates Inc.

Provide EV/GP
for Molecular Templates Inc.

Provide EV/EBITDA
for Molecular Templates Inc.

Provide EV/EBIT
for Molecular Templates Inc.

Provide EV/OCF
for Molecular Templates Inc.

Provide EV/FCFF
for Molecular Templates Inc.

Provide EV/IC
for Molecular Templates Inc.

Show me price targets
for Molecular Templates Inc made by professional analysts.

What are the Revenue projections
for Molecular Templates Inc?

How accurate were the past Revenue estimates
for Molecular Templates Inc?

What are the Net Income projections
for Molecular Templates Inc?

How accurate were the past Net Income estimates
for Molecular Templates Inc?

What are the EPS projections
for Molecular Templates Inc?

How accurate were the past EPS estimates
for Molecular Templates Inc?

What are the EBIT projections
for Molecular Templates Inc?

How accurate were the past EBIT estimates
for Molecular Templates Inc?

Compare the revenue forecasts
for Molecular Templates Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Molecular Templates Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Molecular Templates Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Molecular Templates Inc compared to its peers.

Compare the P/E ratios
of Molecular Templates Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Molecular Templates Inc with its peers.

Analyze the financial leverage
of Molecular Templates Inc compared to its main competitors.

Show all profitability ratios
for Molecular Templates Inc.

Provide ROE
for Molecular Templates Inc.

Provide ROA
for Molecular Templates Inc.

Provide ROIC
for Molecular Templates Inc.

Provide ROCE
for Molecular Templates Inc.

Provide Gross Margin
for Molecular Templates Inc.

Provide Operating Margin
for Molecular Templates Inc.

Provide Net Margin
for Molecular Templates Inc.

Provide FCF Margin
for Molecular Templates Inc.

Show all solvency ratios
for Molecular Templates Inc.

Provide D/E Ratio
for Molecular Templates Inc.

Provide D/A Ratio
for Molecular Templates Inc.

Provide Interest Coverage Ratio
for Molecular Templates Inc.

Provide Altman Z-Score Ratio
for Molecular Templates Inc.

Provide Quick Ratio
for Molecular Templates Inc.

Provide Current Ratio
for Molecular Templates Inc.

Provide Cash Ratio
for Molecular Templates Inc.

What is the historical Revenue growth
over the last 5 years for Molecular Templates Inc?

What is the historical Net Income growth
over the last 5 years for Molecular Templates Inc?

What is the current Free Cash Flow
of Molecular Templates Inc?

Financials

Balance Sheet Decomposition
Molecular Templates Inc

Current Assets 16.8m
Cash & Short-Term Investments 11.5m
Receivables 250k
Other Current Assets 5m
Non-Current Assets 18.6m
PP&E 16.6m
Other Non-Current Assets 2.1m
Current Liabilities 17.3m
Accounts Payable 1.5m
Accrued Liabilities 6.8m
Other Current Liabilities 9m
Non-Current Liabilities 13.9m
Other Non-Current Liabilities 13.9m
Efficiency

Earnings Waterfall
Molecular Templates Inc

Revenue
57.3m USD
Operating Expenses
-67.8m USD
Operating Income
-10.5m USD
Other Expenses
2.3m USD
Net Income
-8.1m USD

Free Cash Flow Analysis
Molecular Templates Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MTEM Profitability Score
Profitability Due Diligence

Molecular Templates Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional ROE
Exceptional 1-Year Revenue Growth
ROE is Increasing
31/100
Profitability
Score

Molecular Templates Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

MTEM Solvency Score
Solvency Due Diligence

Molecular Templates Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
36/100
Solvency
Score

Molecular Templates Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MTEM Price Targets Summary
Molecular Templates Inc

Wall Street analysts forecast MTEM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MTEM is 16.5 USD .

Lowest
Price Target
Not Available
Average
Price Target
16.5 USD
1 022% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

MTEM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MTEM Price
Molecular Templates Inc

1M 1M
-16%
6M 6M
-76%
1Y 1Y
-78%
3Y 3Y
-99%
5Y 5Y
-98%
10Y 10Y
-100%
Annual Price Range
1.47
52w Low
1.47
52w High
9.3
Price Metrics
Average Annual Return -13.41%
Standard Deviation of Annual Returns 95.61%
Max Drawdown -99%
Shares Statistics
Market Capitalization 9.7m USD
Shares Outstanding 6 583 880
Percentage of Shares Shorted 0.88%

MTEM Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Molecular Templates Inc Logo
Molecular Templates Inc

Country

United States of America

Industry

Biotechnology

Market Cap

9.7m USD

Dividend Yield

0%

Description

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company is headquartered in Austin, Texas and currently employs 261 full-time employees. The company went IPO on 2005-02-04. The firm utilizes its biologic drug platform to design and generate engineered toxin bodies (ETBs). ETBs use a genetically engineered version of the Shiga-like Toxin A subunit (SLTA), a ribosome inactivating bacterial protein. The firm is developing ETBs for various targets, including CD20, CD38, HER2, and PD-L1. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of multiple myeloma. HER2 is clinically validated as a target for the treatment of solid tumors including breast and gastric cancer. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.

Contact

TEXAS
Austin
9301 Amberglen Blvd Ste 100
+15128961555.0
https://mtem.com/

IPO

2005-02-04

Employees

261

Officers

CEO, Chief Scientific Officer & Director
Dr. Eric E. Poma Ph.D.
President, CFO, Treasurer & Principal Accounting Officer
Ms. Jason S Kim
Chief Operating Officer
Ms. Kristen Quigley B.A.
Chief Strategy Officer & Head of IR
Dr. Grace Kim
Senior VP & Head of CMC Development
Dr. Joseph Phillips Ph.D.
Chief Medical Officer
Dr. Maurizio Voi M.D.

See Also

Discover More
What is the Intrinsic Value of one MTEM stock?

The intrinsic value of one MTEM stock under the Base Case scenario is 3.52 USD.

Is MTEM stock undervalued or overvalued?

Compared to the current market price of 1.47 USD, Molecular Templates Inc is Undervalued by 58%.